Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of AD-NP1 in Healthy Volunteers
NCT07762001Phase 1Active, not recruiting
- Start
- Jun 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AD-NP1 (8 cohorts). Primary endpoint: Safety and tolerability of escalating doses of a single IV dose of AD-NP1. Started Jun 2026; status: active, not recruiting.
02
Drugs
AD-NP1
Beyond the preview
Go deeper on NCT07762001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07762001.